Repository logo
  • English
  • äø­ę–‡
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • äø­ę–‡
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pureå­øč”“äŗŗę‰åŗ«č½‰å…„
  4. Human parvovirus B19 VP1u‐induced osteoclastogenesis is enhanced by RANKL in RAW264.7 macrophage cells
 
  • Details
Options

Human parvovirus B19 VP1u‐induced osteoclastogenesis is enhanced by RANKL in RAW264.7 macrophage cells

Journal
Molecular Medicine Reports
Date Issued
2026-09-01
Author(s)
BOR-SHOW TZANG  
TSAI-CHING HSU  
DOI
10.3892/mmr.2026.13951
URI
https://www.scopus.com/pages/publications/105044827958
https://scholars.csmu.edu.tw/handle/123456789/31642
Abstract
Human parvovirus B19 (B19V) DNA and antigens are frequently detected in synovial tissue; however, the mecha‑ nisms linking B19V infection to bone destruction remain unclear. The present study investigated the B19V VP1 unique region (VP1u) and its influence on osteoclast differentia‑ tion. RAW264.7 macrophages were cultured with or without receptor activator of NF‑κB ligand (RANKL) and B19V‑VP1u for up to 7 days. Tartrate‑resistant acid phosphatase staining, bone resorption assays and western blotting were used to assess osteoclastogenesis. The involvement of signaling pathways was investigated using an anti‑TNF‑α antibody, and inhibitors of MAPK, ERK, JNK and NF‑κB signaling. B19V‑VP1u alone induced osteoclastogenesis in a dose‑ and time‑dependent manner and, in the presence of RANKL, further increased osteoclast size and number. B19V‑VP1u significantly increased pit resorption, and nuclear factor of activated T cells (NFAT)2 (also known as NFATc1), cathepsin K, c‑FOS, MMP9 and dendritic cell‑specific transmembrane protein expression. The inhibition of ERK, JNK, NF‑κB or TNF‑α did not alter the effects of VP1u, whereas blockade of p38 MAPK nearly abolished VP1u‑induced osteoclastogenesis. These findings indicate that B19V‑VP1u acts as a strong osteoclastogenic factor through a p38‑dependent but TNF‑α‑independent pathway in vitro. The present study supports a dual mechanism of B19V‑induced bone pathology, whereby VP1u directly promotes osteoclastogenesis, whereas inflammation medi‑ ates bone resorption via cytokine signaling. Targeting viral protein‑host signaling interactions may offer novel therapeutic approaches for B19V‑associated bone erosion.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback